Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Lack of Effectiveness of Repurposed Drugs for COVID-19 Treatment
Miguel Ángel Martı́nez
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 59

Showing 26-50 of 59 citing articles:

Drug Interactions for Patients with Respiratory Diseases Receiving COVID-19 Emerged Treatments
Marios Spanakis, Athina Patelarou, Evridiki Patelarou, et al.
International Journal of Environmental Research and Public Health (2021) Vol. 18, Iss. 21, pp. 11711-11711
Open Access | Times Cited: 12
Investigation of structural analogs of hydroxychloroquine for SARS-CoV-2 main protease (Mpro): A computational drug discovery study
Saima Reyaz, Alvea Tasneem, Gyan Prakash, et al.
Journal of Molecular Graphics and Modelling (2021) Vol. 109, pp. 108021-108021
Open Access | Times Cited: 11
Drug Repurposing and Molecular Insights in the Fight Against Breast Cancer
Ruchi Jakhmola Mani, Vikash Sharma, Sohini Singh, et al.
Biomedical & Pharmacology Journal (2024) Vol. 17, Iss. 2, pp. 831-861
Open Access | Times Cited: 1
Strategies to identify candidate repurposable drugs: COVID-19 treatment as a case example
Ali Sajid Imami, Robert E. McCullumsmith, Sinead M. O’Donovan
Translational Psychiatry (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 10
Deciphering COVID-19 host transcriptomic complexity and variations for therapeutic discovery against new variants
Jing Xing, Rama Shankar, Meehyun Ko, et al.
iScience (2022) Vol. 25, Iss. 10, pp. 105068-105068
Open Access | Times Cited: 7
Comprehensive Fragment Screening of the SARS‐CoV‐2 Proteome Explores Novel Chemical Space for Drug Development
Hannes Berg, Maria A. Wirtz Martin, Nadide Altincekic, et al.
Angewandte Chemie (2022) Vol. 134, Iss. 46
Open Access | Times Cited: 7
Efficacy and safety of hydroxychloroquine as pre-and post-exposure prophylaxis and treatment of COVID-19. Systematic review and meta-analysis of blinded, placebo-controlled, randomized clinical trials
Paulo Ricardo Martins‐Filho, Lis Campos Ferreira, Luana Heimfarth, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 9
Effects of hydroxychloroquine and its metabolites in patients with connective tissue diseases
Duygu Eryavuz Onmaz, Dilek Tezcan, Sedat Abuşoğlu, et al.
Inflammopharmacology (2021) Vol. 29, Iss. 6, pp. 1795-1805
Open Access | Times Cited: 9
Discovering the fibroblastic reticular cell in the immune tumor microenvironment in lymphoma
Adam Yuh Lin, Leo I. Gordon
Journal of Clinical Investigation (2023) Vol. 133, Iss. 13
Open Access | Times Cited: 3
COVID-19 vaccine guidelines was numerous in quantity but many lack transparent reporting of methodological practices
Zijun Wang, Hui Liu, Yang Li, et al.
Journal of Clinical Epidemiology (2021) Vol. 144, pp. 163-172
Open Access | Times Cited: 6
Thinking Outside the Box: Utilizing Nontraditional Animal Models for COVID-19 Research
Sachithra Gunasekara, Miruthula Tamil Selvan, Craig Miller, et al.
International Journal of Translational Medicine (2022) Vol. 2, Iss. 1, pp. 113-133
Open Access | Times Cited: 4
SARS-CoV-2-induced Host Metabolic Reprogram (HMR): Nutritional Interventions for Global Management of COVID-19 and Post-Acute Sequelae of COVID-19 (PASC)
A. Satyanarayan Naidu, Fereidoon Shahidi, Chin‐Kun Wang, et al.
Journal of Food Bioactives (2022), pp. 1-42
Open Access | Times Cited: 4
Bioactive compounds as potential angiotensin-converting enzyme II inhibitors against COVID-19: a scoping review
Pedro Henrique de Matos, Thalita Prates da Silva, Amanda Benites Mansano, et al.
Inflammation Research (2022) Vol. 71, Iss. 12, pp. 1489-1500
Open Access | Times Cited: 4
Efficacy and Safety of A Novel Antiviral Preparation in ICU-Admitted Patients with COVID-19: A Phase III Randomized Controlled Trial
Hossein Faramarzi, Amirhossein Sahebkar, AHMAD HOSSEINPOUR, et al.
Research Square (Research Square) (2022)
Open Access | Times Cited: 3
Drugs repurposing for SARS-CoV-2: new insight of COVID-19 druggability
Sujit Kumar Debnath, Monalisha Debnath, Rohit Srivastava, et al.
Expert Review of Anti-infective Therapy (2022) Vol. 20, Iss. 9, pp. 1187-1204
Closed Access | Times Cited: 3
Digital Health, Telemedicine, and Patient-centeredness: New Trends for Italian Healthcare after COVID-19
Gabriella Piscopo, Simona Mormile, Paola Adinolfi, et al.
MECOSAN (2024), Iss. 125, pp. 29-46
Closed Access
Efficacy and safety of a novel antiviral herbal preparation in ICU-admitted patients with COVID-19: A phase III double-blinded controlled trial.

PubMed (2024) Vol. 14, Iss. 2, pp. 215-228
Closed Access
Nanomaterial’s role against SARS-CoV-2 pandemic and beyond
Ragini Singh, Joel Saji, Anamika Saini, et al.
Royal Society of Chemistry eBooks (2024), pp. 177-201
Closed Access
Identification of Natural Inhibitors of SARS-CoV-2 Main Protease (Mpro) via Structure-Based Virtual Screening and Molecular Dynamics Simulations

Letters in Applied NanoBioScience (2024) Vol. 13, Iss. 4, pp. 176-176
Open Access
In-Vitro Screening of Repurposed Drug Library against Severe Acute Respiratory Syndrome Coronavirus-2
Gudepalya Renukaiah Rudramurthy, Radha Krishan Shandil, Shridhar Narayanan
Medical Research Archives (2023) Vol. 11, Iss. 2
Open Access | Times Cited: 1
From Evidence-Based Corona Medicine to Organismic Systems Corona Medicine
James A. Marcum, Felix Tretter
Philosophy of Medicine (2023) Vol. 4, Iss. 1
Open Access | Times Cited: 1
Efficacy and safety of a novel antiviral preparation in ICU-admitted patients with COVID-19: a phase III randomized controlled trial
Hossein Faramarzi, Amirhossein Sahebkar, Ahmad Hosseinpour, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 3
Marine mollusc extracts—Potential source of SARS‐CoV‐2 antivirals
Rebecca L. Pedler, Peter Speck
Reviews in Medical Virology (2021) Vol. 32, Iss. 4
Open Access | Times Cited: 2
What Should Be Learned From Repurposed Antivirals Against SARS-CoV-2?
Miguel Ángel Martı́nez
Frontiers in Microbiology (2022) Vol. 13
Open Access | Times Cited: 1
In silico Tools and Techniques for Screening and Development of Peptide-Based Spike Protein Inhibitors against Novel Coronavirus (Sars-CoV-2)
Raghunath Satpathy
Jordan Journal of Biological Sciences (2022) Vol. 15, Iss. 05, pp. 729-738
Open Access | Times Cited: 1

Scroll to top